1. Home
  2. ZJYL vs MOLN Comparison

ZJYL vs MOLN Comparison

Compare ZJYL & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JIN MEDICAL INTERNATIONAL LTD.

ZJYL

JIN MEDICAL INTERNATIONAL LTD.

HOLD

Current Price

$1.99

Market Cap

145.9M

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

N/A

Current Price

$4.21

Market Cap

170.5M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ZJYL
MOLN
Founded
2006
2004
Country
China
Switzerland
Employees
273
N/A
Industry
Industrial Specialties
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
145.9M
170.5M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
ZJYL
MOLN
Price
$1.99
$4.21
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$8.38
AVG Volume (30 Days)
38.9K
1.5K
Earning Date
08-20-2025
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$374.07
P/E Ratio
$18.40
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.10
$3.53
52 Week High
$4.50
$5.36

Technical Indicators

Market Signals
Indicator
ZJYL
MOLN
Relative Strength Index (RSI) 38.64 50.27
Support Level $1.94 $4.13
Resistance Level $2.59 $4.21
Average True Range (ATR) 0.18 0.15
MACD -0.04 -0.04
Stochastic Oscillator 18.25 42.05

Price Performance

Historical Comparison
ZJYL
MOLN

About ZJYL JIN MEDICAL INTERNATIONAL LTD.

Jin Medical International Ltd, along with its subsidiaries, mainly offers rehabilitation equipment. It is engaged in the design, development, manufacturing, and sales of wheelchairs and other assistive living aid products for use by people with disabilities or impaired mobility. The group's product offering includes wheelchairs and wheelchair components, oxygen concentrators, bathing machines, respiratory and walking aids, oxygen chambers, beauty instruments, and nano products, among others. Wheelchairs are currently its key revenue-generating product. The products are sold to dealers in Japan and China, and to some extent to dealers located in the United States, Canada, Australia, Korea, Israel, Singapore, and other regions. Geographically, the group generates maximum revenue from Japan.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.

Share on Social Networks: